Scholarlink

Background <p>Treatment effect of high-dose intravenous selenium remains controversial in patients with sepsis or septic shock. Here, we reanalyzed data from the randomized placebo-controlled trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis (SISPCT) to reveal possible treatment differences according to established sepsis phenotypes.</p> Methods <p>In this secondary data analysis of the SISPCT trial all 1089 patients of the original study were included. Patients were assigned to one of the four phenotypes by comparing patient variables with the Sepsis Endotyping in Emergency Care (SENECA) validation cohort. Survival analyses were performed using Kaplan–Meier and log-rank tests.</p> Results <p>No robust effect of selenium on mortality and other outcome parameters could be determined in any sepsis phenotype. Phenotype frequencies were markedly different in our study cohort compared to previous reports (<i>α</i>: 2.2%, <i>β</i>: 6.3%, <i>γ</i>: 68.0%, <i>δ</i>: 23.4%). Differences in mortality between the respective phenotypes were not significant overall; however, 28-day mortality showed a lower mortality for the <i>α</i>- (20.8%) and <i>β</i>-phenotype (20.3%), followed by the <i>γ</i>- (27.1%), and <i>δ</i>-phenotype (28.5%).</p> Conclusions <p>Application of the four sepsis phenotypes to the SISPCT study cohort showed discrete but non-significant mortality differences within 28&#xa0;days. However, beneficial treatment effects of high-dose intravenous selenium were still not detectable after categorizing the SISPCT study cohort according to four phenotype criteria.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment effect of intravenous high-dose selenium in sepsis phenotypes: a retrospective analysis of a large multicenter randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月14日

查看全文
  • David I. Radke,
  • Holger Bogatsch,
  • Christoph Engel,
  • Frank Bloos,
  • Patrick Meybohm,
  • Michael Bauer,
  • Anna Lulu Homayr,
  • Christian Stoppe,
  • Gunnar Elke,
  • Matthias Lindner,
  • Axel Nierhaus,
  • Josef Briegel,
  • Ulrich Jaschinski,
  • Onnen Mörer,
  • Andreas Weyland,
  • Matthias Gründling,
  • Stefan Kluge,
  • Stefan Utzolino,
  • Sebastian Stehr,
  • Maximilian Ragaller,
  • Frank Brunkhorst,
  • Herwig Gerlach

摘要

Background

Treatment effect of high-dose intravenous selenium remains controversial in patients with sepsis or septic shock. Here, we reanalyzed data from the randomized placebo-controlled trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis (SISPCT) to reveal possible treatment differences according to established sepsis phenotypes.

Methods

In this secondary data analysis of the SISPCT trial all 1089 patients of the original study were included. Patients were assigned to one of the four phenotypes by comparing patient variables with the Sepsis Endotyping in Emergency Care (SENECA) validation cohort. Survival analyses were performed using Kaplan–Meier and log-rank tests.

Results

No robust effect of selenium on mortality and other outcome parameters could be determined in any sepsis phenotype. Phenotype frequencies were markedly different in our study cohort compared to previous reports (α: 2.2%, β: 6.3%, γ: 68.0%, δ: 23.4%). Differences in mortality between the respective phenotypes were not significant overall; however, 28-day mortality showed a lower mortality for the α- (20.8%) and β-phenotype (20.3%), followed by the γ- (27.1%), and δ-phenotype (28.5%).

Conclusions

Application of the four sepsis phenotypes to the SISPCT study cohort showed discrete but non-significant mortality differences within 28 days. However, beneficial treatment effects of high-dose intravenous selenium were still not detectable after categorizing the SISPCT study cohort according to four phenotype criteria.